Skip Navigation

David S Mathai, M.D.

David S Mathai, M.D.

Headshot of David S Mathai
  • Assistant of Psychiatry and Behavioral Sciences



Research Interests

Psychedelic Medicine; Therapeutic Ketamine; Psychodynamic Psychotherapy; Trauma Recovery; Ethics in Psychiatry more


Johns Hopkins Bayview Medical Center

5510 Nathan Shock Drive
Baltimore, MD 21224 map


David Mathai, MD completed his medical training and Psychiatry Residency at Baylor College of Medicine in Houston, Texas before joining the Department of Psychiatry and Behavioral Sciences at The Johns Hopkins University School of Medicine.

He is interested in interdisciplinary approaches to psychopharmacology research and has studied behavioral models of addiction and cognitive impairment, neuropsychiatric effects of cannabis, and antidepressant properties of ketamine. His current postdoctoral work focuses on applications of psychedelic medicine within phenomenologically- and psychologically-oriented frameworks. He is fascinated by psychedelics as a tool for therapeutic change and recognizes the need for thoughtful and nuanced treatment paradigms that account for the complexity of human experience. He is also interested in contextual factors shaping drug response, the judicious use of medication, and serving as a liaison between existing clinical and academic communities.

Clinically, Dr. Mathai works as a psychiatrist for Addiction Treatment Services (ATS) at Johns Hopkins Bayview Medical Center and as a guide for psilocybin sessions. He has received recognition for medical student education and psychotherapy along with awards for his scholarly work. more


  • Assistant of Psychiatry and Behavioral Sciences

Departments / Divisions



  • MD; Baylor College of Medicine (2017)


  • Psychiatry; Baylor College of Medicine (2021)

Board Certifications

  • American Board of Psychiatry and Neurology (Psychiatry-General) (2021)

Research & Publications

Selected Publications

View all on PubMed

Mathai DS, McCathern AG, Guzick AG, Schneider SC, Weinzimmer SA, Cepeda SL, Garcia-Romeu A, Storch EA. Parental Attitudes Toward Use of Ketamine in Adolescent Mood Disorders and Suicidality. Journal of Child and Adolescent Psychopharmacology. 2021;31(8):553-561

Mathai DS, Meyer MJ, Storch EA, Kosten TR. The relationship between subjective effects induced by a single dose of ketamine and treatment response in patients with major depressive disorder: A systematic review. Journal of Affective Disorders. 2020; 264:123-129

Verrico CD, Mathai DS, Gu H, Sampson AR, Lewis DA. Recovery from impaired working memory performance during chronic Δ-9-tetrahydrocannabinol administration to adolescent rhesus monkeys. Journal of Psychopharmacology. 2020; 34(2):211-222

Mathai DS, Holst M, Rodgman C, Haile CN, Keller J, Hussain MZ, Kosten TR, Newton TF, Verrico CD. Guanfacine attenuates adverse effects of dronabinol (THC) on working memory in adolescent-onset heavy cannabis users: A pilot study. The Journal of Neuropsychiatry and Clinical Neurosciences. 2017; 30(1):66-76

Mathai DS, Mathew SJ. Ketamine. In: Schatzberg AF, Nemeroff CB, eds. The American Psychiatric Publishing Textbook of Psychopharmacology. Fifth Edition. American Psychiatric Publishing; 2017

Contact for Research Inquiries

5510 Nathan Shock Drive
Baltimore, MD 21224 map

Activities & Honors


  • Hilde Bruch Award for Excellence in Psychiatry
  • American Psychiatric Association Research Colloquium Junior Investigator Award
  • Stacia Micheletto Award in Psychodynamic Psychiatry
Is this you? Edit Profile
back to top button